Procedure
Peripheral blood draws
Peripheral blood draws is a medical procedure with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
4
Max Phase
—
Type
PROCEDURE
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
active_not_recruiting125%
completed125%
terminated250%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
NCT04397003
completedphase_1
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03072771
terminatedphase_1
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
NCT03122106
terminatedphase_1
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
NCT03121677
Clinical Trials (4)
Showing 4 of 4 trials
NCT04397003Phase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
NCT03072771Phase 1
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03122106Phase 1
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
NCT03121677Phase 1
Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 4